Literature DB >> 19085953

Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.

Jinsheng Guo1, Johnny Loke, Feng Zheng, Feng Hong, Steven Yea, Masayuki Fukata, Mirko Tarocchi, Olivia T Abar, Hongjin Huang, John J Sninsky, Scott L Friedman.   

Abstract

UNLABELLED: In a recent study, a single nucleotide polymorphism (SNP) of the Toll-like receptor 4 (TLR4) gene (c.1196C>T [rs4986791, p.T399I]) emerged as conferring protection from fibrosis progression compared to a major, wild-type (WT) CC allele (p.T399). The present study examined the functional linkage of this SNP, along with another common, highly cosegregated TLR4 SNP (c.896A>G [rs4986790, p.D299G]), to hepatic stellate cell (HSC) responses. Both HSCs from TLR4(-/-) mice and a human HSC line (LX-2) reconstituted with either TLR4 D299G and/or T399I complementary DNAs were hyporesponsive to lipopolysaccharide (LPS) stimulation compared to those expressing WT TLR4, as assessed by the expression and secretion of LPS-induced inflammatory and chemotactic cytokines (i.e., monocyte chemoattractant protein-1, interleukin-6), down-regulation of bone morphogenic protein and the activin membrane-bound inhibitor expression (an inhibitory transforming growth factor beta pseudoreceptor), and activation of a nuclear factor kappaB (NF-kappaB)-responsive luciferase reporter. In addition, spontaneous apoptosis, as well as apoptosis induced by pathway inhibitors of NF-kappaB, extracellular signal-regulated kinase (ERK), and phosphatidylinositol 3-kinase were greatly increased in HSCs from either TLR4(-/-) or myeloid differentiation factor 88(-/-) (a TLR adaptor protein) mice, as well as in murine HSCs expressing D299G and/or T399I SNPs; increased apoptosis in these lines was accompanied by decreased phospho-ERK and Bcl-2.
CONCLUSION: TLR4 D299G and T399I SNPs that are associated with protection from hepatic fibrosis reduce TLR4-mediated inflammatory and fibrogenic signaling and lower the apoptotic threshold of activated HSCs. These findings provide a mechanistic link that explains how specific TLR4 SNPs may regulate the risk of fibrosis progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19085953      PMCID: PMC2891538          DOI: 10.1002/hep.22697

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Unresponsiveness of MyD88-deficient mice to endotoxin.

Authors:  T Kawai; O Adachi; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-07       Impact factor: 31.745

Review 2.  The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis.

Authors:  A M Elsharkawy; F Oakley; D A Mann
Journal:  Apoptosis       Date:  2005-10       Impact factor: 4.677

3.  Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria.

Authors:  Frank P Mockenhaupt; Jakob P Cramer; Lutz Hamann; Miriam S Stegemann; Jana Eckert; Na-Ri Oh; Rowland N Otchwemah; Ekkehart Dietz; Stephan Ehrhardt; Nicolas W J Schröder; Ulrich Bienzle; Ralf R Schumann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

4.  Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity.

Authors:  Herbert C Yohe; Kimberley A O'Hara; Jane A Hunt; Tamar J Kitzmiller; Sheryl G Wood; Jenna L Bement; William J Bement; Juliana G Szakacs; Steven A Wrighton; Judith M Jacobs; Vsevolod Kostrubsky; Peter R Sinclair; Jacqueline F Sinclair
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-01-26       Impact factor: 4.052

5.  Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling.

Authors:  Prasad Rallabhandi; Jessica Bell; Marina S Boukhvalova; Andrei Medvedev; Eva Lorenz; Moshe Arditi; Val G Hemming; Jorge C G Blanco; David M Segal; Stefanie N Vogel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Conditional signaling by Toll-like receptor 4.

Authors:  Gregory J Brunn; Marlo K Bungum; Geoffrey B Johnson; Jeffrey L Platt
Journal:  FASEB J       Date:  2005-02-28       Impact factor: 5.191

7.  Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans.

Authors:  E Novo; F Marra; E Zamara; L Valfrè di Bonzo; L Monitillo; S Cannito; I Petrai; A Mazzocca; A Bonacchi; R S M De Franco; S Colombatto; R Autelli; M Pinzani; M Parola
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

8.  TLR4-mediated survival of macrophages is MyD88 dependent and requires TNF-alpha autocrine signalling.

Authors:  Eleuterio Lombardo; Alberto Alvarez-Barrientos; Beatriz Maroto; Lisardo Boscá; Ulla G Knaus
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 9.  Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.

Authors:  Tarik Asselah; Ivan Bièche; Valérie Paradis; Pierre Bedossa; Michel Vidaud; Patrick Marcellin
Journal:  Semin Liver Dis       Date:  2007-02       Impact factor: 6.115

10.  Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans.

Authors:  S Taudorf; K S Krabbe; R M G Berg; K Møller; B K Pedersen; H Bruunsgaard
Journal:  Clin Exp Immunol       Date:  2008-02-25       Impact factor: 4.330

View more
  98 in total

1.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Authors:  Andrew J Paris; Zohar Snapir; Cindy D Christopherson; Shirley Y Kwok; Ursula E Lee; Zahra Ghiassi-Nejad; Peri Kocabayoglu; John J Sninsky; Josep M Llovet; Chaim Kahana; Scott L Friedman
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 2.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines.

Authors:  Andrew M Miller; Norio Horiguchi; Won-Il Jeong; Svetlana Radaeva; Bin Gao
Journal:  Alcohol Clin Exp Res       Date:  2011-02-01       Impact factor: 3.455

5.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

Review 6.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

7.  Biliary Epithelial Cells Are Not the Predominant Source of Hepatic CXCL12.

Authors:  Yedidya Saiman; Tatsuki Sugiyama; Noa Simchoni; Carlo Spirli; Meena B Bansal
Journal:  Am J Pathol       Date:  2015-04-29       Impact factor: 4.307

8.  Toll like receptor 4 D299G associates with disease progression in Caucasian patients with chronic HBV infection: relationship with gender.

Authors:  Annarosa Cussigh; Carlo Fabris; Giovanna Fattovich; Edmondo Falleti; Sara Cmet; Davide Bitetto; Eleonora Bignulin; Pierluigi Toniutto
Journal:  J Clin Immunol       Date:  2012-10-24       Impact factor: 8.317

Review 9.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

10.  Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease.

Authors:  Hui-Hui Tan; M Isabel Fiel; Qinghua Sun; Jinsheng Guo; Ronald E Gordon; Lung-Chi Chen; Scott L Friedman; Joseph A Odin; Jorge Allina
Journal:  J Immunotoxicol       Date:  2009-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.